Clinical Trial Update: Plasma Lipoprotein Response to Glucagon-like Peptide-2 [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial update on plasma lipoprotein response to glucagon-like peptide-2 in hyperlipidemias.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemias

Snippet

Sponsor: University Health Network, Toronto | Conditions: Hyperlipidemias | Phase 2, Phase 3 | Status: COMPLETED